Who is sponsoring NCT03205735?

NCT03205735 is sponsored by Centre Antoine Lacassagne.

What drugs are being tested in NCT03205735?

Interventions in NCT03205735: lymphocyte DPD dosage.

What condition does NCT03205735 study?

NCT03205735 studies Metastatic or Locally-advanced Digestive Cancer.

Is NCT03205735 still recruiting?

NCT03205735 is currently status unknown. Last updated 2 July 2021.

Last reviewed 2021-07-02 · How we verify

NCT03205735: DPD DIG

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Enzymatic Activity of Lymphocyte Dihydropyrimidine Dehydrogenase DPD in the Blood as a Predictive and Prognostic Factor in Patients With Digestive Cancer in the First or Second Metastatic Line

Status unknown Last updated 2 July 2021

What this trial tests

trial testing lymphocyte DPD dosage in Metastatic or Locally-advanced Digestive Cancer in 200 participants. Status unknown.

Timeline

29 June 2017

Primary endpoint
29 September 2021

29 December 2021

Quick facts

Lead sponsor	Centre Antoine Lacassagne
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	200
Start date	29 June 2017
Primary completion	29 September 2021
Estimated completion	29 December 2021
Sites	1 location across France

Drugs / interventions tested

lymphocyte DPD dosage

Conditions studied

Metastatic or Locally-advanced Digestive Cancer — all drugs for Metastatic or Locally-advanced Digestive Cancer →

Sponsor

Centre Antoine Lacassagne — full company profile →

Who can join

18 and older, any sex, with Metastatic or Locally-advanced Digestive Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

An observational study of a prospective, analytical, monocentric cohort which does not modify the patient care because the phenotyping of the dihydropyrimidine déshydrogénase DPD (lymphocyte activity) is already carried out in routine hospital. The analysis will be based on clinical, radiological and biological criteria.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Centre Antoine Lacassagne trials

Trials by the same sponsor.

NCT07429487 — Assessment of Adherence to Remotely Monitored Physical Activity Tracked on a Smartwatch, and Its Impact on Reducing Fati · NA · not yet recruiting
NCT06782451 — Development of Preclinical Models Derived From Tumors With a Molecular Abnormality of Interest to Test Their Sensitivity · NA · recruiting
NCT06606366 — Study on the Contribution of the Genetic Tumor Profile Obtained by Circulating Tumor DNA Analysis in the Multidisciplina · NA · recruiting
NCT06400849 — Comparison of the Efficacy of Cryotherapy Combined With Compression in Preventing Neuropathy · NA · recruiting
NCT06029218 — Analysis of the Toxicity and Efficacy of Daily 1 vs 2 Beam Proton Therapy · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03205735 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centre Antoine Lacassagne
Last refreshed: 2 July 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03205735.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing